Why Is Teladoc Health (TDOC) Stock Down -27.23% Today?
Key Takeaways
- Teladoc Health shares plummeted 27.23% in Thursday's session after the company reported a second-quarter revenue miss and slashed its full-year guidance.
- The primary catalyst was Q2 revenue of $606.9 million falling short of the $615.4 million Wall Street consensus, coupled with sharply reduced forward revenue projections.
- BetterHelp's accelerating cash-pay decline took center stage, with the mental health segment's direct-to-consumer revenue deteriorating faster than management had anticipated.
- Competitive headwinds from OpenAI's expanded ChatGPT health features added a layer of sector-wide pressure on telehealth names.
- High short interest of nearly 16% of float likely amplified the selloff as bearish positioning paid off dramatically.
- Traders are now watching whether the company's accelerated insurance rollout at BetterHelp can stabilize revenue trends in the second half of the year.
Opening Summary
TDOC, the stock of Teladoc Health, Inc.—the global leader in virtual care services spanning primary care, mental health, and chronic condition management—suffered its worst single-day percentage decline since February 2024 on Thursday. Shares closed the prior session at $9.18 but cratered to approximately $6.68 in intraday trading, marking a stunning drop of roughly 27%. The selloff was triggered by second-quarter 2026 earnings released after the bell on Wednesday, which revealed a revenue miss and a significant cut to full-year guidance, overwhelming any optimism around the company's narrower-than-expected loss per share.
Q2 Earnings Miss and Deteriorating BetterHelp Revenue
Teladoc Health reported second-quarter 2026 consolidated revenue of $606.9 million, down 4% year-over-year and below the $615.4 million consensus estimate. While the company posted a smaller-than-expected net loss of $0.21 per share—beating estimates for a $0.25 loss—investors zeroed in squarely on the top-line shortfall and the weakening trajectory of the BetterHelp direct-to-consumer mental health platform.
BetterHelp segment revenue came in at $212.6 million, representing a 12% year-over-year decline. CEO Chuck Divita acknowledged that cash-pay revenue pressure "accelerated further in late May and into June," beyond the assumptions underlying the company's prior outlook. Although insurance-covered demand for BetterHelp services exceeded expectations, provider capacity constraints limited the company's ability to convert that demand into sessions and revenue. The segment's adjusted EBITDA margin collapsed to just 0.2%, underscoring the profitability squeeze.
Full-Year Guidance Slashed
Perhaps most damaging to investor confidence was the steep reduction in full-year revenue guidance. Teladoc now expects fiscal 2026 revenue in the range of $2.362 billion to $2.447 billion, representing a year-over-year decline of 3% to 7%. At the midpoint, this implies a roughly 5% cut from prior expectations. Third-quarter revenue guidance of $569 million to $609 million also came in below Street forecasts, signaling that management does not expect a quick turnaround.
The guidance cut reflects updated assumptions for BetterHelp's cash-pay business, with management explicitly stating it is prioritizing the growing insurance market over stabilizing the legacy direct-pay model. While the strategic pivot toward insurance may strengthen long-term positioning, the near-term revenue erosion has rattled the market.
Competitive Pressure From AI and Sector Sentiment
Adding to the bearish narrative, OpenAI launched an expanded Health experience inside ChatGPT for U.S. users on the same day, allowing individuals to link medical records, lab results, and wearable data into conversational AI interactions. Both TDOC and peer AMWL (American Well) retreated on Thursday, as investors weighed the risk that AI-driven tools could erode demand for paid virtual consultations for lower-acuity informational needs. While Teladoc concurrently unveiled Teladoc One—a connected virtual care model integrating AI—the announcement was overshadowed by the earnings fallout and the broader competitive overhang.
Market Context and Trading Activity
The magnitude of Thursday's decline was extraordinary by any measure. The stock gapped below its 30-day moving average, a key technical level that had provided support since May. Trading volume was set to finish dramatically above the daily average, reflecting capitulation-style selling. The selloff landed TDOC on the short-sale restricted (SSR) list, and with short interest already sitting at 15.96% of the float—equivalent to roughly six days of buying power—the move likely featured an element of momentum-driven liquidation. The broader healthcare and telehealth sector felt the ripple effects, but Teladoc's decline far outpaced peers, confirming that company-specific fundamentals drove the action.
What Comes Next for TDOC
Looking ahead, all eyes will be on Teladoc's execution of its accelerated insurance rollout at BetterHelp. Management continues to expect 2026 insurance revenue within its previously communicated range, but the success of rapidly scaling provider capacity to meet insurance-driven demand remains a critical question mark. The Integrated Care segment, which posted 1% revenue growth and a 16.5% adjusted EBITDA margin, offers a modest bright spot, but it is not large enough to offset BetterHelp's challenges on its own.
Upcoming catalysts include any signs of stabilization in BetterHelp monthly active user trends, further details on Teladoc One adoption rates when select clients begin using the platform in September 2026, and third-quarter results that will test whether the lowered guidance bar proves conservative or merely the first of further cuts. With 19 of 26 analysts already at "Hold" ratings prior to the earnings debacle, further downgrades could add selling pressure in the days ahead.
Trending AI Robots
In volatile market environments like today's, traders increasingly turn to data-driven tools to navigate rapid price swings. Tickeron's Trending AI Robots page spotlights a curated selection of AI-powered trading bots from a universe of hundreds covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots spanning diverse strategies, timeframes, and performance metrics across numerous symbols. For traders seeking algorithmic insights, exploring the Trending AI Robots page offers a window into which strategies are resonating in the current market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
TDOC sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for TDOC moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TDOC as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for TDOC turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TDOC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for TDOC entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TDOC's RSI Indicator exited the oversold zone, 24 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where TDOC advanced for three days, in 190 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
TDOC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.817) is normal, around the industry mean (7.432). TDOC has a moderately low P/E Ratio (0.000) as compared to the industry average of (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.462) is also within normal values, averaging (6.065).
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. TDOC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TDOC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a telephone and online video consultation service
Industry ServicestotheHealthIndustry
Advertisement